
Commentary|Videos|December 7, 2025
Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML
Fact checked by: Ashling Wahner , Chris Ryan
Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.
Advertisement
“We had a cohort of 21 patients, one-third of which [had] KMT2A rearrangements. [In this population], the overall response rate was high, [at 86%]. The complete response [CR]/CR with partial hematologic recovery rate was also [86%].”
Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed findings from the phase 2 SAVE trial (NCT05360160) evaluating revumenib (Revuforj) plus decitabine, cedazuridine, and venetoclax (Venclexta) in patients with newly diagnosed acute myeloid leukemia.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
2
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma
3
Immune-Targeting Vaccine Shows Promise Intercepting Cancer in Patients With Lynch Syndrome
4
FDA Grants Orphan Drug Designation to Gotistobart in Squamous NSCLC
5




































